FDA Proposes to Update Tamiflu, Relenza Drug Labels

WSJ.com: "WASHINGTON -- U.S. Food and Drug Administration medical officers are proposing new language on antiviral influenza drugs Tamiflu and Relenza to discuss neuropsychiatric events seen among some users of the medications. Tamiflu, by Roche Holdings AG and Relenza by GlaxoSmithKline PLC, are antiviral drugs approved to treat influenza. The FDA posted a safety review of the drugs to its Web site Friday for a Nov. 27 meeting of the agency's pediatric advisory committee, which is made up of outside medical experts"